Clinical Trial Update: Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis [Phase 3]

View source ↗

Summary

This Phase 3 trial update presents long-term safety and efficacy data for ESK-001 in adults with moderate-to-severe plaque psoriasis; the study is currently not…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis
• Psoriasis

Drugs mentioned

• ESK-001

Snippet

Sponsor: Alumis Inc | Conditions: Plaque Psoriasis, Psoriasis (PsO) | Phase 3 | Status: ACTIVE_NOT_RECRUITING